Menu
Search
|

Menu

Close
X

Zealand Pharma A/S ZEAL.OQ (NASDAQ Stock Exchange Global Select Market)

16.64 USD
-1.23 (-6.88%)
As of 8:00 PM GMT
Previous Close 17.87
Open 17.34
Volume 6,002
3m Avg Volume 1,886
Today’s High 17.39
Today’s Low 16.64
52 Week High 18.90
52 Week Low 11.30
Shares Outstanding (mil) 30.75
Market Capitalization (mil) 3,751.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.70 Mean rating from 10 analysts

KEY STATS

Revenue (mm, DKK)
FY18
38
FY17
136
FY16
231
EPS (DKK)
FY18
18.905
FY17
-9.713
FY16
-6.711
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
12.16
8.39
Price to Book (MRQ)
vs sector
17.22
5.27
Price to Cash Flow (TTM)
vs sector
148.70
24.12
Total Debt to Equity (MRQ)
vs sector
80.46
16.02
LT Debt to Equity (MRQ)
vs sector
78.44
11.35
Return on Investment (TTM)
vs sector
-26.95
13.82
Return on Equity (TTM)
vs sector
-67.92
15.24

EXECUTIVE LEADERSHIP

Alf Nicklasson
Independent Chairman of the Board, Since 2015
Salary: --
Bonus: --
Adam Steensberg
Interim Chief Executive Officer, Executive Vice President, Chief Medical and Development Officer (CMDO), Since 2019
Salary: --
Bonus: --
Rosemary Crane
Independent Vice Chairman of the Board, Since 2015
Salary: --
Bonus: --
Mats Blom
Chief Financial Officer, Executive Vice President, Member of the Executive Management, Since 2017
Salary: kr.2,496,000.00
Bonus: kr.999,000.00
Ivan Moeller
Senior Vice President, Technical Development & Operations, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Smedeland 36
GLOSTRUP     2600

Phone:

Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area offers ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment. Furthermore, the Company collaborates with a number of partners, such as Sanofi, Helsinn, Boehringer Ingelheim, Abbvie and Eli Lilly.

SPONSORED STORIES